On May 9, 2024, Takeda Pharmaceutical Company announced a multi-year program aimed at enhancing growth and improving core operating profit margins through organizational changes and cost efficiencies. The initiative is expected to incur JPY 140 billion in restructuring expenses in FY2024, aiming for a profit margin improvement of 100-250 basis points annually towards a target of low- to mid-30%.